↓ Skip to main content

Buflomedil for intermittent claudication

Overview of attention for article published in Cochrane database of systematic reviews, March 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
73 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Buflomedil for intermittent claudication
Published in
Cochrane database of systematic reviews, March 2013
DOI 10.1002/14651858.cd000988.pub4
Pubmed ID
Authors

Tine LM de Backer, Robert Vander Stichele

Abstract

Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined. This is an update of a Cochrane review first published in 2000, and previously updated in 2007 and 2008.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 73 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 16%
Student > Ph. D. Student 11 15%
Student > Bachelor 11 15%
Researcher 11 15%
Other 8 11%
Other 9 12%
Unknown 11 15%
Readers by discipline Count As %
Medicine and Dentistry 30 41%
Nursing and Health Professions 12 16%
Psychology 5 7%
Unspecified 3 4%
Social Sciences 3 4%
Other 7 10%
Unknown 13 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2020.
All research outputs
#8,008,694
of 14,738,308 outputs
Outputs from Cochrane database of systematic reviews
#8,569
of 11,034 outputs
Outputs of similar age
#66,653
of 150,986 outputs
Outputs of similar age from Cochrane database of systematic reviews
#80
of 109 outputs
Altmetric has tracked 14,738,308 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,034 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.6. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 150,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 109 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.